Arizona State Retirement System Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Arizona State Retirement System raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 566,542 shares of the biopharmaceutical company’s stock after buying an additional 8,691 shares during the period. Arizona State Retirement System’s holdings in Bristol Myers Squibb were worth $32,644,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Life Cycle Investment Partners Ltd purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter worth about $34,406,000. Lazard Asset Management LLC raised its position in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the last quarter. Axxcess Wealth Management LLC lifted its holdings in shares of Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after purchasing an additional 21,196 shares in the last quarter. Callan Family Office LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $3,575,000. Finally, BlackRock Inc. grew its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Down 3.3%

Shares of BMY stock traded down $2.19 during mid-day trading on Tuesday, hitting $64.63. 9,522,716 shares of the company’s stock were exchanged, compared to its average volume of 11,932,380. The stock has a market cap of $132.02 billion, a price-to-earnings ratio of 14.24, a PEG ratio of 0.32 and a beta of 0.23. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The stock has a 50-day simple moving average of $63.09 and a two-hundred day simple moving average of $59.96.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm posted $1.46 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research reports. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Guggenheim reissued a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Citigroup restated a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Finally, Bank of America dropped their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.